SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

BRIEF-Zai Lab Announces First Patient Dosed In Greater China In Global Registrational Clinical Trial Of Efgartigimod In Primary Immune Thrombocytopenia

reuters.com · 11/11/2021 07:31
BRIEF-Zai Lab Announces First Patient Dosed In Greater China In Global Registrational Clinical Trial Of Efgartigimod In Primary Immune Thrombocytopenia

- Zai Lab Ltd ZLAB:

  • ZAI LAB ANNOUNCES FIRST PATIENT DOSED IN GREATER CHINA IN GLOBAL REGISTRATIONAL CLINICAL TRIAL OF EFGARTIGIMOD IN PRIMARY IMMUNE THROMBOCYTOPENIA

Source text for Eikon: ID:nGNXb6NMG

Further company coverage: ZLAB


((Reuters.Briefs@thomsonreuters.com;;))